263 related articles for article (PubMed ID: 9683035)
1. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer.
Pairet M; van Ryn J; Schierok H; Mauz A; Trummlitz G; Engelhardt G
Inflamm Res; 1998 Jun; 47(6):270-6. PubMed ID: 9683035
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
4. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.
Engelhardt G; Bögel R; Schnitzler C; Utzmann R
Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265
[TBL] [Abstract][Full Text] [Related]
5. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
7. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers.
Stichtenoth DO; Wagner B; Frölich JC
J Investig Med; 1997 Feb; 45(2):44-9. PubMed ID: 9084574
[TBL] [Abstract][Full Text] [Related]
8. Flurbiprofen and enantiomers in ophthalmic solution tested as inhibitors of prostanoid synthesis in human blood.
van Haeringen NJ; van Sorge AA; Van Delft JL; Carballosa Coré-Bodelier VM
J Ocul Pharmacol Ther; 2000 Aug; 16(4):345-52. PubMed ID: 10977130
[TBL] [Abstract][Full Text] [Related]
9. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.
Blain H; Boileau C; Lapicque F; Nédélec E; Loeuille D; Guillaume C; Gaucher A; Jeandel C; Netter P; Jouzeau JY
Br J Clin Pharmacol; 2002 Mar; 53(3):255-65. PubMed ID: 11874389
[TBL] [Abstract][Full Text] [Related]
10. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
[TBL] [Abstract][Full Text] [Related]
12. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
[TBL] [Abstract][Full Text] [Related]
13. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.
King JN; Rudaz C; Borer L; Jung M; Seewald W; Lees P
Res Vet Sci; 2010 Jun; 88(3):497-506. PubMed ID: 20004922
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.
Engelhardt G
Br J Rheumatol; 1996 Apr; 35 Suppl 1():4-12. PubMed ID: 8630636
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs.
Jones CJ; Streppa HK; Harmon BG; Budsberg SC
Am J Vet Res; 2002 Nov; 63(11):1527-31. PubMed ID: 12428662
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis.
Ochi T; Goto T
Br J Pharmacol; 2002 Feb; 135(3):782-8. PubMed ID: 11834626
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
Kay-Mugford P; Benn SJ; LaMarre J; Conlon P
Am J Vet Res; 2000 Jul; 61(7):802-10. PubMed ID: 10895904
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
Famaey JP
Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory activity of myricetin-3-O-beta-D-glucuronide and related compounds.
Hiermann A; Schramm HW; Laufer S
Inflamm Res; 1998 Nov; 47(11):421-7. PubMed ID: 9865500
[TBL] [Abstract][Full Text] [Related]
20. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
